CHAIRED BY:
Philip Hewitt, UK and Eurotox Registered Toxicologist, Global Head of Early Investigative Toxicology, Merck Healthcare KGaA
Stefan Przyborski, Professor of Cell Technology, Durham university

Development and application of human organs and tissues in vitro
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity.

SMi’s 3D Cell Culture Conference will explore advances of organ and lab-on-a-chip, microphysiological systems, applications of technology and case studies, imaging, high throughput screening and advances in 3D cell culture models which make up core components within the 3D Cell Culture field.

Bioprinting has become increasingly efficient and accurate in building in vitro tissue models with the potential to provide pathologically relevant responses and model human disease mechanisms. Bio-printed structures yield phenotypic endpoints that are comparable with clinical studies and can provide a realistic prediction of clinical efficacy. The use of bioprinting is growing in big pharma companies as an alternative to organ-on-a-chip systems.

For the first time ever the NEW 3D Bioprinting Focus Day on 18 February 2020 will explore case studies from big pharma, biotech’s and academia exploring how bioprinting is being used in industry highlighting projects looking at stem cell therapy, drug screening and extracellular matrix scaffolds.

Event Hashtag: #SMi3DCellCulture

FEATURED SPEAKERS INCLUDE:

• Leonard Both, Senior Quality Assessor, Biologicals/Biotechnology Unit, MHRA
• Veronique Barban, Expert Virology, Research and Nonclinical Safety Department, Sanofi Pasteur
• Simone Stahl, Associate Principal Scientist, ADME Sciences, Clinical Pharmacology and Safety Sciences, AstraZeneca
• Wendy Rowan, Scientific Director, Novel Human Genetics Research Unit, GSK
• Jason Ekert, Head of Complex In Vitro Models, GSK
• Samuel Jackson, Programme Manager, Disease Models Efficacy and Safety Pharmacology, NC3RS

KEY TOPICS FOR 2019 INCLUDE:

• Learn from leading pharma companies to benchmark against their applications of 3D technology
• Explore case studies of 3D cell culture, high throughput screening, imaging and microphysiological systems in industry
• Hear about the latest technology advances allowing 3D bioprinting to revolutionise in vitro models
• Discuss organ-on-chip technologies and their applications to replace the use of animals in pharmaceutical research
• Participate in a panel discussion on adopting new technologies for 3D models

View the full agenda: http://www.3d-cellculture.com/PJWL

WHO SHOULD ATTEND?

Biotech / Pharma Companies – Team Leader, Junior Principle investigator, Cell and Molecular Scientist, Chief Scientific Officer, Deputy Director, Manager, Founder, CEO, Head, Director, Programme Manager, Lab Head, Toxicologist

Academia Professor – Cell Technology, Stem Cell Sciences, Biochemistry, Protein Technology and Tissue Engineering

Solution Providers – Manager, Head of, CEO, Director, Founder, Account Manager, President, CSO, Executive, Managing Director, Vice President, COO

Organisations / Regulatory – Director, Senior Science Advisor, Scientific Officer

EARLY BIRD-RATES

• REGISTER BY 31ST OCTOBER AND SAVE £400
• REGISTER BY 29TH NOVEMBER AND SAVE £200
• REGISTER BY 13TH DECEMBER AND SAVE £100